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2Abstract
Apoptosis represents a key anti-cancer therapeutic effector mechanism. 
During apoptosis, mitochondrial outer membrane permeabilisation (MOMP) typically
kills cells even in the absence of caspase activity. Caspase activity can also have a 
variety of unwanted consequences that include DNA-damage. We therefore 
investigated whether MOMP-induced caspase-independent cell death (CICD) might 
be a better way to kill cancer cells. We find that cells undergoing CICD display potent 
pro-inflammatory effects relative to apoptosis. Underlying this, MOMP was found to 
stimulate NF-B activity through the down-regulation of inhibitor of apoptosis (IAP)
proteins. Strikingly, engagement of CICD displays potent anti-tumorigenic effects, 
often promoting complete tumour regression in a manner dependent on intact 
immunity. Our data demonstrate that by activating NF-B, MOMP can exert 
additional signalling functions besides triggering cell death. Moreover, they support 
a rationale for engaging caspase-independent cell death in cell-killing anti-cancer 
therapies.
3Introduction
Mitochondrial outer membrane permeabilisation or MOMP, is often essential 
for apoptosis; MOMP enables the release of mitochondrial proteins, including
cytochrome c, that activate caspases leading to rapid cell death
1
. Nevertheless, cells 
typically die following MOMP even in the absence of caspase activity, through a
process called caspase-independent cell death (CICD). This defines MOMP as a point-
of-no-return that commits a cell to die 
2
. 
Apoptosis is broadly considered a positive process that can serve to both 
prevent and treat cancer
3
. However, various data argue that apoptosis may also 
have detrimental effects that are potentially tumour promoting
4, 5
. For instance, sub-
lethal apoptotic stress can engage caspase activity in the absence of cell death, 
leading to DNA damage and genomic instability
6-8
. We have previously found that 
these effects were dependent upon MOMP in a limited cohort of mitochondria, 
permitting sub-lethal caspase activity
6
. 
Caspases are not required for MOMP-induced killing; this finding, coupled to 
the negative effects of engaging sub-lethal caspase activity, led us to ask whether
CICD might be a better way to kill cancer cells. We find that under caspase-deficient 
conditions, MOMP can trigger TNF-dependent necroptosis as a form of CICD. 
Underlying this, MOMP triggers NF-B activation during CICD, leading to pro-
inflammatory and immunogenic effects. Most importantly, therapeutic engagement 
of CICD displays significantly enhanced anti-tumour activity relative to apoptosis.
Results
Mitochondrial permeabilisation can engage necroptosis as a form of caspase-
independent cell death
Mitochondria are not required to execute necroptosis; however whether 
they can initiate this type of cell death is unclear 
9
. We investigated whether
mitochondrial permeabilisation could trigger necroptosis as a type of caspase-
independent cell death (CICD). To induce apoptosis, SVEC cells were treated with the 
4BH3-mimetic ABT-737 +/- the pan-caspase inhibitor Q-VD-OPh. Caspase activity was 
determined by Western blotting for PARP1 cleavage and cell viability was measured
by propidium iodide (PI) exclusion. ABT-737 treatment led to PARP1 cleavage that
was blocked by Q-VD-OPh treatment (Figure 1A). ABT-737 triggered cell death 
irrespective of caspase-inhibition (Figure 1B) but in a MOMP-dependent manner, 
since MCL-1 expression (which is not effectively inhibited by ABT-737) prevented cell 
death (Figure 1C, Supplemental Figures 1A, 1B, 1C)
10
. To investigate whether
necroptosis could contribute to CICD, we inhibited RIPK1 and RIPK3 – two kinases 
often essential for necroptosis
11
. SVEC cells were treated with ABT-737 +/- Q-VD-
OPh together with necrostatin-1 (nec-1), to inhibit RIPK1, or following RIPK3 shRNA-
knockdown (Supplemental Figure 1D). RIPK3 knockdown prevented necroptosis 
induced by TNF/zVAD treatment, confirming functional inhibition (Figure 1D). 
Neither nec-1 treatment nor RIPK3 knockdown had any effect upon ABT-737 
mediated apoptosis (Figure 1E). Nevertheless, inhibition of RIPK1 or RIPK3 reduced
CICD following BH3-mimetic treatment, demonstrating that necroptosis can be 
engaged following mitochondrial permeabilisation (Figure 1E). We investigated this 
further using BCL-xL dependent SVEC cells generated using our mito-priming method 
3
. SVEC cells expressing GFP-tBID 2A BCL-xL (BCL-xL dependent SVEC cells) were 
treated with ABT-737 +/- Q-VD-OPh. Alternatively, we used BCL-xL dependent SVEC 
cells in which mitochondrial-dependent caspase activity was inhibited by APAF-1 
shRNA knockdown 
3
. Cell viability was measured using SYTOX Green exclusion and 
Incucyte cell imaging. Verifying their BCL-xL survival dependency, ABT-737 treatment 
led to rapid cell death (Figure 1F) and with expected slower kinetics, in the presence 
of Q-VD-OPh or following APAF-1 knockdown (Figure 1F). Q-VD-OPh treatment 
completely prevented PARP1, caspase-3, -7 and BID cleavage confirming effective 
caspase inhibition (Figure 1G and Supplemental Figure 1E). Using these cells we 
investigated whether necroptosis could contribute to CICD. BCL-xL dependent SVEC 
cells were treated with ABT-737 together with Q-VD-OPh and necroptosis was 
inhibited by nec-1 treatment, RIPK3 knockdown or by CRISPR/Cas-9 mediated 
deletion of the essential necroptosis executioner protein MLKL (Figures 1H, 1I and 1J, 
Supplemental Figures 1F - H). In all cases, cell death was reduced following ABT-
5737/Q-VD-OPh treatment. Therefore, mitochondrial permeabilisation can engage 
necroptosis as a form of caspase-independent cell death.
MOMP induces TNF synthesis under caspase-deficient conditions
We reasoned that MOMP might trigger necroptosis directly by activating
RIPK1/RIPK3 or, indirectly, via TNF signalling. To discriminate these possibilities, SVEC 
cells were treated to undergo CICD in the presence of nec-1 (to inhibit RIPK1) or 
Enbrel (TNF-receptor-II/IgG fusion protein) to inhibit TNF signalling. Cell viability was 
measured by PI exclusion (Figure 2A). As before, ABT-737/Q-VD-OPh induced CICD in 
a nec-1 sensitive manner. Neither Enbrel nor nec-1 treatment impacted on ABT-737 
mediated apoptosis (Figure 2A). However, inhibition of TNF signalling by Enbrel
treatment reduced cell-death following ABT-737/Q-VD-OPh treatment that was not 
further inhibited by nec-1 treatment (Figure 2A). Similar results were obtained using 
BCL-xL-dependent-SVEC cells (Figure 2B). This demonstrates that MOMP-induced
necroptosis requires TNF. In a reciprocal manner, exogenous TNF massively 
enhanced CICD following ABT-737 treatment that was inhibited by either RIPK3 
knockdown or nec-1 treatment (Figure 2C). Therefore, under caspase-inhibited 
conditions, MOMP can engage and sensitise to TNF-dependent necroptosis. We 
asked whether MOMP could trigger TNF synthesis. BCL-xL dependent SVEC cells 
were treated with ABT-737 +/- Q-VD-OPh and analysed by qRT-PCR for Tnf mRNA 
transcript level (Figure 2D). Under caspase-inhibited conditions, ABT-737 treatment 
led to an increase in Tnf transcript level (Figure 2D) in a MOMP-dependent manner
(Figure 2E, Supplemental Figure 1I). Using an ELISA, we also confirmed an increase in 
extracellular TNF protein level following engagement of CICD (Figure 2F). To extend 
these findings, we used cells in which mitochondrial-dependent caspase activity was 
inhibited by APAF-1 knockdown
3
 or by CRISPR/Cas-9 deletion of caspase-9 
(Supplemental Figure 1J). In both settings, ABT-737 treatment led to an increase in 
TNF transcript levels (Figures 2G, 2H). The MOMP-dependent increase of Tnf
transcript was necroptosis independent since it was not impacted by MLKL deletion
(Supplemental Figure 1K). Finally, we assayed Tnf transcript levels in BCL-xL-
dependent-MEFs following ABT-737 treatment in the presence of Q-VD-OPh. Similar 
to SVEC cells, Tnf mRNA was also increased in MEFs following ABT-737 treatment,
6dependent on caspase inhibition (Figure 2I). 
Mitochondrial permeabilisation activates NF-B
Given a major role of TNF in inflammation, we aimed to understand how 
MOMP could drive inflammatory signals in caspase-deficient settings, hypothesising 
that MOMP might activate NF-B - a key pro-inflammatory transcriptional regulator.
BCL-xL dependent SVEC cells were treated with ABT-737 and NF-B activation was 
measured by NF-B p65 nuclear translocation. Importantly, ABT-737 treatment led 
to NF-B activation in a manner that was significantly increased under caspase-
deficient conditions (Figures 3A and 3B). BAX/BAK deleted SVEC cells failed to 
activate NF-B following ABT-737 treatment, demonstrating its MOMP dependence 
(Figures 3C, 3D, Supplemental Figure 2A). Inhibiting mitochondrial-dependent 
caspase activity by APAF-1 shRNA-knockdown or by caspase-9 CRISPR/Cas9 deletion 
also enabled NF-B activation following ABT-737 treatment (Supplemental Figures 
2B, 2C). Moreover, CRISPR/Cas9-mediated deletion of IKK or NEMO (also called IKK
) inhibited NF-B p65 nuclear translocation following ABT-737/Q-VD-OPh treatment 
(Supplemental Figures 2D, 2E). Consistent with an ability of MOMP to activate NF-
B, IB phosphorylation and degradation was detected following ABT-737 
treatment in caspase-deficient settings. Loss of IB, but not phosphorylation was 
also observed in cells treated with ABT-737 to undergo apoptosis, in line with IB
being a reported caspase substrate (Figure 3E)
12
. Using luciferase-based reporter 
constructs, ABT-737 treatment was also found to increase NF-B transcriptional 
activity under caspase-inhibited conditions (Figure 3F). Combined ABT-737/Q-VD-
OPh treatment also led to NF-B activation in MEF and HeLa cells (Supplemental 
Figure 2F). Importantly, neither Enbrel treatment nor MLKL-deletion affected ABT-
737/Q-VD-OPh induced NF-B p65 translocation, demonstrating that MOMP-induced 
NF-B activation is TNF and necroptosis independent (Supplemental Figures 2G and 
2H). To investigate whether Tnf mRNA up-regulation following MOMP required NF-
B we expressed IB
SR 
(super repressor) - a non-degradable IB that inhibits NF-B
nuclear translocation 
13
. Inhibition of NF-B activity by IB
SR
expression was verified
7by inhibition of NF-B p65 nuclear translocation following MOMP and increased cell 
death following TNF treatment (Figure 3G, Supplemental Figures 2I, 2J). Importantly, 
IB
SR
expression completely prevented Tnf mRNA up-regulation following ABT-737 
treatment, confirming its NF-B dependence (Figure 3H). IB
SR
expression also 
inhibited cell death following ABT-737/Q-VD-OPh treatment, consistent with a role 
for MOMP-dependent TNF synthesis in necroptosis engagement (Supplemental 
Figure 2K). These data demonstrate that under caspase-deficient conditions, MOMP 
potently activates NF-B leading to the expression of pro-inflammatory TNF.
MOMP activates NF-B through IAP down-regulation and NIK activation
We next sought to understand how mitochondrial permeabilisation could 
trigger NF-B activity. Small molecules called SMAC-mimetics can activate NF-B by 
causing IAP protein degradation leading to NIK stabilisation and activation 
14, 15
. 
Because these molecules mimic the mitochondrial protein SMAC (also called 
DIABLO), which is released from mitochondria following MOMP – we hypothesised
that MOMP might activate NF-B through a similar mechanism (Supplemental Figure 
3A). BCL-xL dependent SVEC cells were treated with ABT-737 together with Q-VD-
OPh or with SMAC-mimetic (SM-83), and cell lysates were probed for c-IAP1, NIK and 
XIAP (Figure 4A). Supporting previous data, SMAC-mimetic (SM-83) treatment led to 
cIAP1 down-regulation and a concomitant increase of NIK (Figure 4A)
14, 15
. 
Phenocopying this effect, combined ABT-737/Q-VD-OPh treatment also triggered 
cIAP1 loss, NIK up-regulation and, additionally, XIAP depletion. cIAP1 and XIAP loss
was partially inhibited by the proteasome inhibitor MG132, indicating that they were 
targeted for proteasomal degradation following MOMP (Supplemental Figure 3B). 
Similar effects were observed in MEF and HeLa cells following ABT-737 treatment
(Supplemental Figure 3C). Demonstrating a MOMP dependency, combined ABT-
737/Q-VD-OPh treatment triggered a loss of cIAP1, XIAP and an increase in NIK that 
was completely blocked in BAX/BAK deleted cells (Figure 4B). These data 
demonstrate that MOMP can signal IAP-protein degradation and NIK up-regulation.
We investigated whether this was required for MOMP-dependent NF-B activity by 
generating NIK-deleted or cIAP2 overexpressing SVEC cells (Supplemental Figure 3D). 
8Cells were treated with ABT-737 in the presence of caspase inhibitor and NF-B
activity was assayed by measuring nuclear translocation of NFB p65 (Figure 4C, 
Supplemental Figures 3E and 3F). Following NIK deletion or cIAP2 over expression,
NF-B activation was strongly suppressed in response to ABT-737/Q-VD-OPh
treatment (Figure 4C, Supplemental Figures 3E and 3F). ABT-737/Q-VD-OPh-
dependent Tnf mRNA up-regulation was also inhibited in NIK deleted or cIAP2
overexpressing cells (Figure 4D). Finally, ectopic cIAP2 expression inhibited up-
regulation of NIK following ABT-737/Q-VD-OPh treatment (Figure 4E). NF-B
transcriptional activity typically occurs following activation of either the canonical or 
the non-canonical (alternative) pathway. Our results support canonical NF-B 
activation following MOMP, however given the well-established association between
NIK with non-canonical NF-B activity, we investigated non-canonical NF-B activity 
following MOMP. Consistent with non-canonical pathway activation following 
MOMP, increased NF-B p100 to p52 processing was observed following ABT-
737/QVD treatment (Supplemental Figure 3G). Nevertheless, inhibiting non-
canonical NF-B activity (by deleting p100 or RelB) did not block canonical NF-B 
activation following MOMP (Supplemental Figures 3H - J).   These data support a 
model that MOMP signals NF-B activation in a manner analogous to SMAC-
mimetics. We therefore investigated the dependence of these effects on
endogenous SMAC and OMI (a mitochondrial protein that also binds IAP proteins 
upon MOMP). E1A/Ras transformed wild-type MEF or SMAC
-/-
OMI
-/-
MEFs were 
treated with a combination of ABT-737 and UMI-77 (MCL-1 inhibitor) to engage 
MOMP and cIAP1 levels were measured (Figure 4F)
16, 17
. cIAP1 was depleted to a 
similar extent in both cell lines, demonstrating that cIAP1 degradation neither
requires SMAC or OMI. Similarly, combined knockdown of SMAC and OMI did not 
rescue cIAP1 or XIAP loss following ABT-737/Q-VD-OPh treatment (Supplemental 
Figure 3K). Accordingly, wild-type MEF and SMAC
-/-
 OMI
-/- 
MEF activated NF-B to a 
similar extent following MOMP (Figure 4G). Besides SMAC and OMI, other 
mitochondrial proteins can bind IAP proteins 
18, 19
. Because these could potentially 
mediate IAP degradation we investigated whether MOMP could trigger IAP 
degradation by a SMAC-like mechanism. XIAP or an XIAP point-mutant (XIAP 
D214S 
9E314S
) unable to bind SMAC were expressed in BCL-2 dependent HeLa cells, and cells 
were treated to undergo MOMP (Figure 4H)
20
. While XIAP was rapidly degraded 
following ABT-263/Q-VD-OPh treatment, the XIAP mutant unable to bind SMAC was 
completely stabilised. This supports a model whereby IAP proteins are degraded by a 
SMAC-like mechanism following MOMP leading to NIK and NF-B activation.  
Mitochondrial permeabilisation activates an NF-B dependent pro-inflammatory 
response
We investigated whether mitochondrial permeabilisation could induce 
additional pro-inflammatory cytokines besides TNF. BCL-xL dependent SVEC cells 
were treated with ABT-737 +/- Q-VD-OPh and culture supernatant was assayed for 
cytokine levels (Figure 5A, Supplemental Figure 4A). Several cytokines tested 
including MCP-1, KC, IL-6, TNF and IL-12, were up-regulated following ABT-737 
treatment dependent on caspase-inhibition (Figure 5A, Supplemental Figure 4A). To 
investigate the NF-B dependence of this pro-inflammatory signature SVEC cells 
expressing IB
SR
were treated with ABT-737 together with Q-VD-OPh. NF-B 
inhibition silenced most cytokines analysed following ABT-737/Q-VD-OPh treatment 
(Figure 5B, Supplemental Figure 4B). Similarly, qRT-PCR analysis also revealed NF-B
dependent transcriptional up-regulation of various cytokines following ABT-737/Q-
VD-OPh treatment (Figure 5C). Pro-inflammatory cytokine up-regulation following 
MOMP was not inhibited in MLKL-deleted cells, demonstrating its necroptosis 
independence (Supplemental Figure 4C). Canonical NF-B activity alone was required 
for MOMP-induced cytokine up-regulation (Supplemental Figures 4D - Η). 
Importantly, mitochondrial permeabilisation has recently been found to trigger a
type I interferon response dependent upon mitochondrial DNA (mtDNA) activating 
the cGAS/STING signalling pathway
21, 22
. We therefore asked whether MOMP-
induced NF-B activity also contributed to the interferon response. SVEC cells 
expressing IB
SR
were treated with ABT-737 together with Q-VD-OPh and an 
interferon response gene signature was assayed by qRT-PCR (Figure 5D). As controls, 
STING signalling was inhibited by CRISPR/Cas-9 STING deletion or by using mtDNA-
depleted ρ
0
SVEC cells (Supplemental Figure 4I and 4J). Consistent with the findings 
10
of others, inhibition of cGAS/STING signalling effectively blocked the interferon 
transcriptional response following MOMP (Supplemental Figure 4K and 4L)
21, 22
. 
Significantly, suppressing NF-B activity by IB
SR
expression, also inhibited the 
interferon transcriptional response (Figure 5D). Given this, we investigated the 
relationship between MOMP-induced NF-B and STING activities. NF-B activity was 
measured by monitoring NF-B p65 nuclear translocation following ABT-737/Q-VD-
OPh treatment in STING deleted or ρ
0
SVEC cells (Figure 5E). MOMP induced NF-B
activity was unaffected in STING deleted and ρ
0
cells, demonstrating that MOMP 
induced NF-B activity neither requires mtDNA nor STING. In agreement, cIAP1 was 
still degraded following MOMP in both ρ
0
and STING-deleted SVEC cells following ABT-
737/Q-VD-OPh treatment (Figure 5F). Finally, we investigated whether MOMP 
dependent NF-B transcriptional targets also required STING signalling. STING-
deleted SVEC cells were treated with ABT-737 together with Q-VD-OPh and cytokine 
transcript levels were measured by qRT-PCR (Figure 5G). Interestingly, while some 
NF-B dependent transcriptional targets were affected by STING-deletion (Mcp-1,
Tnf) others (Kc, Gm-csf) were not (Figure 5G), highlighting a differential requirement 
for STING-activity following MOMP.
MOMP dependent NF-B signalling within dying cells promotes macrophage
activation
We next investigated whether engaging mitochondrial apoptosis versus CICD
could elicit different paracrine effects. BCL-xL dependent SVEC cells were incubated 
with ABT-737 +/- Q-VD-OPh and culture supernatant was transferred to primary 
bone marrow derived macrophages (BMDMs). Macrophage activation towards an 
M1, pro-inflammatory or an M2, anti-inflammatory state was assayed by qRT-PCR 
for transcripts characteristic of either state (Figure 6A). Importantly, media from cells 
undergoing CICD promoted macrophage activation towards an M1-phenotype, as 
determined by an increase in M1-associated transcript levels, whereas no effect was 
observed using media from apoptotic cells (Figure 6A). Consistent with this, BMDMs
incubated with media from cells undergoing CICD also displayed an increase in the 
M1-associated marker, CD86 (Figure 6B). Media transferred from SVEC cells 
11
undergoing CICD following APAF-1 knockdown or caspase-9 deletion also activated 
macrophages towards an M1-phenotype (Figure 6C, Supplemental Figures 5A and 
5B). These effects required MOMP but not necroptosis, since media transferred from 
ABT-737/Q-VD-OPh treated BAX/BAK deleted cells failed to activate macrophages
whereas media from MLKL deleted cells still activated macrophages (Figure 6D, 
Supplemental Figures 5C and 5D). Significantly, NF-B inhibition (through IB
SR
expression) completely prevented the ability of cells undergoing CICD to promote 
M1-polarisation (Figure 6E). Inhibiting MOMP-dependent NF-B activation by 
deletion of NIK, NF-B p65, NEMO or by cIAP2 overexpression also had inhibitory 
effects (Supplemental Figures 5E - 5H). These results demonstrate that the ability of
CICD to promote M1-macrophage polarisation requires MOMP dependent NF-B 
activity. Because M1-macrophages are associated with anti-tumourigenic properties 
23
 we asked if tumour cells undergoing CICD could also activate macrophages 
towards an M1-profile. Primary tumour cells were isolated from a Myc-driven mouse 
model of pancreatic ductal adenocarcinoma (PDAC) and treated with ABT-737 
together with Q-VD-OPh. Consistent with MOMP-dependent transcriptional up-
regulation, TNF and IFN transcript levels increased following treatment
(Supplemental Figure 5I). Culture supernatant was transferred to primary BMDMs
and macrophage activation state was determined by qRT-PCR and flow-cytometry 
(Figures 6F and 6G). Under CICD conditions, media from PDAC cells also promoted
polarisation of macrophages towards an M1-state (Figures 6F and 6G). We 
investigated what factor(s) produced by cells undergoing CICD could promote 
macrophage activation, focusing initially on TNF. SVEC cells were treated to undergo 
CICD and media was transferred to wild-type macrophages +/- Enbrel or to BMDMs 
derived from TNFR-1
-/-
 mice and macrophage activation was assessed (Supplemental 
Figures 5J and 5K). In both cases, TNF signalling inhibition abrogated but did not 
abolish macrophage activation. Given this, coupled to our finding and that of others 
21, 22
that cells undergoing CICD produce IFNled us to carry out similar experiments 
in the presence of neutralising IFN antibody. IFN neutralisation either alone or in 
combination with Enbrel (to block TNF) also inhibited macrophage activation 
(Supplemental Figure 5L) to some extent, demonstrating that TNF and IFN
12
contribute to CICD-induced macrophage activation. These data show that apoptosis 
and CICD can exert differential paracrine effects. Importantly, cells undergoing CICD 
can promote macrophage inflammatory activation towards a potentially anti-
tumourigenic phenotype that requires MOMP-driven NF-B activity.
Caspase-independent cell death displays potent anti-tumourigenic effects 
Our findings suggest that under caspase-deficient conditions, MOMP-
dependent NF-B activity could confer therapeutic benefit in cancer treatment. To 
test this, we performed tumour allograft and treatment experiments using the 
colorectal cancer line CT26. These cells are RIPK3 deficient, allowing investigation of
anti-tumourigenic CICD effects in the absence of necroptosis 
24
. CT26 cells were 
transduced with GFP-tBID 2A BCL-2 encoding retrovirus to generate a 
heterogeneous population of BH3-mimetic sensitive and resistant cells. These were
either caspase-proficient or rendered deficient in MOMP-induced caspase activity 
through APAF-1 knockdown (Supplemental Figure 6A). BH3-mimetic treatment 
induced a similar extent of MOMP in the presence or absence of APAF-1 
(Supplemental Figure 6A). Cells were subcutaneously injected into BALB/c mice as 
syngeneic hosts. Following tumourigenesis, mice were treated with the BH3-mimetic 
ABT-263 (the orally available bioequivalent of ABT-737) to induce either tumour-cell 
apoptosis or CICD (Supplemental Figure 6B). Caspase activity was only detectable 
under apoptotic conditions, as confirmed by immunohistochemical staining for active 
caspase-3 (Supplemental Figure 6C). Supporting our in vitro data, Luminex assay 
revealed increased systemic cytokine levels; the majority of them pro-inflammatory, 
under conditions where tumour-specific CICD had been engaged (Figure 7A, 
Supplemental Figure 6D). We next investigated immune cell infiltration into tumours
after CICD induction or apoptosis. While total macrophage infiltration was similar 
following either CICD or apoptosis (Supplemental Figure 6E), areas of macrophage 
accumulation were prevalent in tumours permissive only for CICD (Supplemental
Figure 6F). Importantly, highly granulated macrophages expressed significant levels 
of MHC-II but not CD206, where CICD had specifically been triggered, mirroring the 
in vitro pro-inflammatory status observed previously (Supplemental Figures 6G, 6H).
13
An increase in T-cell infiltration was specifically observed following engagement of 
tumour cell CICD (Figures 7B, 7C). Together with our previous results, these data 
argue that CICD may be more immunogenic than apoptosis. Based on this, we 
directly addressed a possible therapeutic benefit of engaging tumour-specific CICD 
compared with apoptosis. BCL-2-dependent control or APAF-1 knockdown CT26 
were subcutaneously injected into BALB/c mice. Once tumours were established, 
mice were treated four times with ABT-263 over a two-week period and tumour 
growth was monitored (Figure 7D). In the presence of vehicle alone, APAF-1 
knockdown tumours grew slower than their wild-type counterparts. Tumour growth 
was unaffected by ABT-263 engagement of apoptosis, however under CICD
conditions, ABT-263 treatment led to a significant overall reduction in tumour 
growth (Figure 7D). Further analysis revealed complete regression in 50% of mice 
bearing APAF-1 knockdown tumours, following ABT-263 treatment (Figure 7E). These 
data show that engaging CICD in tumours elicits inflammatory and immune effects. 
Most importantly, CICD displays potent anti-tumour effects, frequently leading to 
complete tumour regression.
CICD anti-tumourigenic effects requires NF-B and intact immunity 
Because engaging tumour CICD can lead to complete tumour regression, we
investigated the role of immunity in mediating these effects. Similar to before, BCL-2-
dependent control or APAF-1 knockdown CT26 were subcutaneously injected into 
BALB/c mice. Following tumour establishment, mice were treated four times with 
ABT-263 over a two-week period. Tumours were isolated at a defined endpoint, then 
analysed by flow-cytometry for tumour infiltrating immune cells. Tumours displaying
regression or outgrowth, were termed as responders or non-responders 
respectively. Consistent with earlier results, APAF-1 knockdown tumours displayed 
the most effective response following ABT-263 treatment (Supplemental Figure 7A). 
Importantly, ABT-263 treatment led to an increase in total macrophage infiltration
(F4/80
+
) as well as an enhancement of activated, anti-tumourigenic macrophage
subsets (NOS2
+
, CD86
+
, MHC-II
+
) in tumours responding to CICD (APAF-1
SH
)(Figure 8A
and Supplemental Figure 7B). Analysis of tumour infiltrating T-cells, revealed an 
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increase in total T-cell infiltrate, comprised of increased CD4
+
 T-helper cells and 
cytotoxic CD8
+
 T-cells specifically in tumours responding to CICD (APAF-
1
SH
)(Supplemental Figure 7C). Furthermore, an increase in IFN
+
CD4
+
 T-helper cells, 
consistent with activation an anti-tumourigenic Th1 response, and activated 
cytotoxic CD8
+
 cells (IFN
+
, GZMB
+
, IFN
+
/GZMB
+
) was identified in tumours 
responding to CICD (Figures 8B and 8C). These results demonstrate that an anti-
tumourigenic immune activation correlates with response following CICD 
engagement. We therefore hypothesized that the beneficial effects of engaging CICD
might be due to an ability of the immune system to control tumour growth. To test 
this, BCL-2-dependent control or APAF-1 knockdown CT26 cells were subcutaneously 
injected into immunocompromised NOD scid gamma c
-/-
(NSG) mice. Following 
tumour establishment, mice were left untreated or repeatedly treated with ABT-263 
and tumour growth was monitored (Figure 8D and Supplemental Figure 7D). 
Importantly, ABT-263 treatment had no effect on tumour growth in NSG mice
thereby supporting a key role for the immune system in mediating the anti-
tumorigenic effects of CICD. APAF-1 knockdown tumours grew with similar kinetics 
to wild-type tumours in NSG mice (Supplemental Figure 7D), unlike their slower 
growth in immuncompetent BALB/c mice (Figure 7D). This may be due to a basal 
level of CICD activating, growth-inhibitory anti-tumour immunity. We carried out 
similar experiments under T-cell depleted conditions.  BCL-2-dependent APAF-1 
knockdown CT26 were subcutaneously injected into BALB/c mice. Once tumours 
were established, mice were treated with ABT-263 and T-cell depleting antibody 
(anti-Thy.1) or isotype control over a two-week period and tumour growth was 
monitored. Anti-Thy.1 treatment effectively depleted T-cells (Supplemental Figures
7E and 7F) and robustly inhibited the anti-cancer effects of engaging CICD, 
completely prevented tumour regression (Figure 8E and Supplemental Figure 7G). 
We addressed whether the anti-cancer effects of engaging CICD were dependent 
upon MOMP-induced NFB activation. NF-B proficient (vector) and deficient 
(NEMO
SH
) BCL-2-dependent APAF-1 knockdown CT26 were subcutaneously injected 
into BALB/c mice (Supplemental Figure 7H). Following tumour formation, mice were 
treated with the BH3-mimetic ABT-263 to induce tumour-cell CICD and tumour 
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growth monitored (Figure 8F). Importantly, while ABT-263 CICD engagement 
promoted complete tumour regression, blocking NF-B signalling through NEMO-
knockdown, inhibited these effects (Figure 8F, Supplemental Figure 7I). Finally, we 
examined the potential clinical relevance of our findings by interrogating the Cancer 
Proteome Atlas (TCPA) 
25
. We investigated the relationship between NF-B, caspase 
activity and treatment outcome in renal cell carcinoma. Phospho-NF-B p65 
S536
 and 
cleaved-caspase 7 were used as measures of NFB and caspase activity (Figure 8G). 
In line with our data, an inverse correlation between NF-B activity and caspase-7 
activity was found (Figure 8G). Importantly, high levels of NF-B activity and low 
levels of caspase-7 activity also correlated with improved prognosis following 
therapy (Figure 8G). These data show that CICD is an immunogenic form of cell 
death, and that both NF-B activity during CICD and immunity are required for its 
anti-tumourigenic effects.   
Discussion
As others have reported 
26
, progressive mitochondrial dysfunction that 
ensues post-MOMP under caspase-inhibited conditions, leads to cell death. 
Nevertheless, our data demonstrates that how MOMP kills - either by apoptosis or 
CICD - has profoundly different effects. Unlike mitochondrial apoptosis, cells 
undergoing CICD display a pro-inflammatory phenotype dependent on NF-B activity
in the dying cell. Importantly, recent studies have shown that MOMP can also 
activate cGAS/STING signalling dependent on mtDNA
21, 22
. While we find that MOMP-
dependent NF-B activation and cGAS/STING signalling are independent events,
both are required for the collective pro-inflammatory effects of CICD. 
How does MOMP activate NF-B? From our data we propose a model that
MOMP activates NF-B in a manner similar to small-molecule SMAC-mimetics. NF-B 
is typically anti-apoptotic
27
, moreover IKK activity can also promote survival through 
NF-B-independent means
28
. Nevertheless, because widespread MOMP represents a 
terminal event, NF-B or IKK activation post- MOMP won’t allow long-term cell 
survival. Our results demonstrate that NIK-dependent canonical NF-B activity is
16
important for the inflammatory and anti-tumour effects we observe. While NIK is 
best associated with activation of non-canonical NF-B activity it has also been 
shown to crosstalk with canonical NF-B activity
29-31
. Indeed, SMAC-mimetics also 
activate canonical NF-B signalling in a manner that can depend on NIK
14, 15, 32
. The 
failure of NIK-deletion to completely prevent NF-B signalling following MOMP
suggests additional MOMP-dependent pathways may also signal NFB activity. 
Importantly, triggering CICD but not apoptosis often led to complete tumour 
regression. Especially under conditions of partial therapeutic response, as our 
experiments mimic, these data suggest that triggering tumour-specific CICD rather 
than apoptosis may be a more effective way to treat cancer. Indeed others have also 
observed enhanced anti-tumourigenic effects treated with cytotoxic agents together 
with caspase inhibitor
33, 34
. Why might CICD be more anti-tumourigenic than 
apoptosis? From our data, we reason that CICD is more immunogenic than apoptosis 
and that this contributes to its increased anti-tumour activity. Mirroring our findings,
NF-B activity has recently been shown to be a key immunogenic determinant of 
necroptotic cell death that is essential for anti-tumour immunity
35
. While
necroptosis is not important for the anti-tumour effects of CICD, NF-B activation is.
Because many cancers are resistant to necroptosis
36
, this significantly broadens the 
potential utility of targeting CICD in cancer. Importantly, caspase activity is neither
required for MOMP-dependent cell death and indeed can have unwanted effects
4
. 
Coupled to our own findings, we propose that engaging CICD as a means of anti-
cancer therapy warrants further investigation.   
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Figure 1. Mitochondrial permeabilisation can engage necroptosis as a form of CICD 
SVEC cells were treated with ABT-737 (10 M) +/- Q-VD-OPh (10 M) and (A)
immunoblotted for PARP and β-Actin. Representative images from three 
independent experiments.
SVEC cells were treated for 72 h with ABT-737 (10 M) +/- caspase inhibitor Q-(B)
VD-OPh (10 M). For (B)(C)(D) and (E) cell viability was measured by flow-cytometry 
and PI exclusion. n=5 independent experiments.
SVEC cells stably expressing LZRS empty vector (vector) or LZRS-MCL-1 were (C)
treated for 72 h with ABT-737 (10 M) +/- Q-VD-OPh (10 M). n=3 independent 
experiments; mean values ± S.E.M
Control or RIPK3
SH
 SVEC cells were treated for 72 h with TNF (20 ng/ml) +/-(D)
caspase inhibitor zVAD-FMK (50 M) and/or RIPK1 inhibitor necrostatin-1 (30 M). 
n=3 independent experiments; mean values ± S.E.M
SVEC cells stably expressing pLKO empty vector (vector) or pLKO-shRIPK3 (E)
(RIPK3
SH
) were treated for 72 h with ABT-737 (10 M) +/-  caspase inhibitor Q-VD-
OPh (10 M) and/or RIPK1 inhibitor necrostatin-1 (30 M). n=3 independent 
experiments; mean values ± S.E.M.
BCL-xL dependent SVEC cells expressing empty vector (pLKO1) or pLKO-(F)
shAPAF-1 (APAF-1
SH
) were treated for 24 h with ABT-737 (10 M) +/- caspase 
inhibitor Q-VD-OPh (30 M). For (F)(H)(I)(J) cell death was measured using an 
IncuCyte imager, measuring SYTOX Green uptake. n=3 independent experiments; 
mean values ± S.E.M.
BCL-xL dependent SVEC cells were treated with ABT-737 (10 μM) +/- Q-VD-(G)
OPh (30 M) then immunoblotted for indicated proteins. Representative images 
from three independent experiments.
BCL-xL dependent SVEC cells stably expressing an empty vector (pLKO1) or (H)
pLKO1-shRIPK3 (RIPK3
SH
) were treated with ABT-737 (10 M) in the presence of 
caspase inhibitor Q-VD-OPh (30 M) and/or necrostatin-1 (30 M). A representative 
time-point shown (16 h).  n=5 independent experiments; mean values ± S.E.M.
Control or MLKL-deleted BCL-xL dependent SVEC cells were treated with TNF (I)
(20 ng/ml) and zVAD-FMK (50 M) +/- necrostatin-1 (30 M). A representative time-
point is shown (21 h). n=3 independent experiments; mean values ± S.E.M.
Control (vector
CRISPR
) or MLKL-deleted (MLKL
CRISPR
) BCL-xL dependent SVEC(J)
cells were treated with ABT-737 (10 M) together with Q-VD-OPh (30 M) and/or 
necrostatin-1 (30 M). A representative time-point is shown (21 h). n=3 independent 
experiments; mean values ± S.E.M.*p<0.05, **p<0.01, ***P<0.001; Holm-Sidak-
corrected one way ANOVA (B), two-tailed unpaired t-test (C, D, E, H, I, J).
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Figure 2. MOMP induces TNF-synthesis under caspase-deficient conditions
SVEC cells were treated (72 h) with ABT-737 (10 M) +/- Q-VD-OPh (10 M) (A)
necrostatin-1 (30 M) or Enbrel (50 g/ml). Cell viability was measured by flow-
cytometry (%PI
+
 cells). n=3 independent experiments; mean values ± S.E.M.
BCL-xL dependent SVEC cells were treated for 22 h with ABT-737 (10 M) (B)
together with Q-VD-OPh (10 μM) or necrostatin-1 (30 M) +/- Enbrel (50 g/ml). cell 
death was measured using an IncuCyte imager, measuring SYTOX Green uptake. n=3
independent experiments; mean values ± S.E.M
BCL-xL dependent control or RIPK3 shRNA SVEC cells were treated as (C)
indicated with ABT-737 (10 M), Q-VD-OPh (30 M) and/or necrostatin-1 (30 M), in 
the presence of TNF (20 ng/ml). Cell death was measured by IncuCyte imager, using 
SYTOX Green uptake, a representative time-point is shown (16 h). n=3 independent 
experiments; mean values ± S.E.M.
BCL-xL dependent SVEC cells were treated with ABT-737 (10 M) +/- Q-VD-(D)
OPh (30 M) and Tnf expression was measured by qRT-PCR. Data represent mean of 
triplicate samples and is representative of three independent experiments. 
Control (vector
CRISPR
) or BAX/BAK deleted BCL-xL dependent SVEC cells (E)
(BAX/BAK
CRISPR
) were treated with ABT-737 (10 M) and Q-VD-OPh (30 M) then Tnf 
expression was measured by qRT-PCR. Data represent the mean of triplicate samples 
and are representative of three independent experiments.
BCL-xL dependent SVEC cells were treated with ABT-737 (10 M) together(F)
with Q-VD-OPh (30 M). Media TNF levels were measured by ELISA. n=3
independent experiments; mean values ± S.E.M.
BCL-xL dependent SVEC cells expressing APAF-1 shRNA (APAF-1
SH
) were (G)
treated with ABT-737 (10 M) and Tnf expression was measured by qRT-PCR.
Control or Caspase-9 deleted BCL-xL dependent SVEC cells were treated with(H)
ABT-737 (10 M) and Tnf expression was measured by qRT-PCR.
BCL-xL dependent E1A/Ras transformed MEFs were treated as in (D) and Tnf (I)
expression was measured by qRT-PCR. For (G)(H)(I) data represent the mean of 
triplicate samples and are representative of three independent experiments. 
*p<0.05, **p<0.01, ***P<0.001; two-tailed unpaired t-test (A, B) Holm-Sidak-
corrected one way ANOVA (F). Statistical source data can be found in Supplementary 
Table 5.
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Figure 3. Mitochondrial permeabilisation activates NF-B
BCL-xL dependent SVEC cells were treated with ABT-737 (10 M) +/- Q-VD-(A)
Oph (30 M) for 1 h, immunostained for p65 and analysed by confocal microscopy. 
TNF (20 ng/ml) was used as positive control for p65 nuclear translocation. Scale bar 
represents 30M. Representative images from three independent experiments.  
Quantification of cells (from A) displaying nuclear p65, minimum 300 cells (B)
were counted per condition. Ctrl: n=15 individual fields, ABT-737: n=15 individual 
fields, ABT-737/QVD: n=18, individual fields TNF: n=15 individual fields  SEM.
BCL-xL dependent SVEC cells deleted for BAX and BAK (BAX/BAK
CRISPR
) or cells (C)
expressing empty vector (vector
CRISPR
) were treated with ABT-737 (10 M) +/- Q-VD-
OPh (30 M) for 6 h then immunostained for p65 and cytochrome c. Scale bar 
represents 30M. Representative images from three independent experiments.  
Quantification of cells in (C) displaying nuclear p65, minimum 300 cells were (D)
counted per condition. Vector
CRISPR
-ctrl: n=15 individual fields, vector
CRISPR
-ABT-
737/QVD: n=16 individual fields, BAX/BAK
CRISPR
-ctrl: n=15 individual fields,
BAX/BAK
CRISPR
 -ABT-737/QVD: n=16 individual fields  SEM.
BCL-xL dependent SVEC cells were treated with ABT-737 (10 M) +/- Q-VD-(E)
OPh (30 M) and blotted for p-IBα, total IBα and -Actin. .Representative image of 
three independent experiments.
BCL-xL dependent SVEC cells transiently expressing two different NFB (F)
reporters (PGL3-TNF reporter 1 or PGL3-NP3 reporter 2 were treated with ABT-737 
(10 M) +/- Q-VD-OPh (30 M) for 3 h and luciferase reporter assay was performed. 
Data represent the mean of duplicate samples and are representative of three 
independent experiments.
BCL-xL dependent SVEC cells stably expressing IB
SR
 or empty vector (PMX) (G)
were treated with ABT-737 (10 M) together with Q-VD-OPh (30 M) or TNF (20 
ng/ml) for 1 h and then immunostained for p65, minimum 300 cells were counted 
per condition. Quantification of cells displaying nuclear p65 was performed. Vector-
ctrl: n=15 individual fields, vector-ABT-737/QVD: n=18 individual fields, vector-
TNF/QVD: n=16 individual fields, IB
SR
-ctrl: n=15 individual fields, IB
SR
-ABT-737/QVD: 
n=15 individual fields, IB
SR
-TNF/QVD: n=15 individual fields  SEM.
BCL-xL dependent SVEC cells stably expressing IB
SR
 or empty vector (PMX) (H)
were treated with ABT-737 (10 M) and Q-VD-OPh (30 M) and Tnf expression was 
measured by qRT-PCR. Data represent the mean of triplicate samples and are 
representative of three independent experiments.
*p<0.05, **p<0.01, ***P<0.001; Tukey-corrected one way ANOVA (B), Tukey-
corrected two way ANOVA (D, G). 
Statistical source data can be found in Supplementary Table 5. Unprocessed original 
scans of blots are shown in Supplementary Figure 9.  .
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Figure 4. MOMP activates NF-B through IAP down-regulation and NIK activation
Cell lysates from BCL-xL dependent SVEC cells treated with SMAC-mimetic (A)
(SM-83, 50 nM) or ABT-737 (10 M) and Q-VD-OPh (30 M, 8h) were immunoblotted 
for indicated proteins. Representative image of three independent experiments.
Control or BAX/BAK deleted BCL-xL dependent SVEC cells were treated with (B)
ABT-737 (10 M) and Q-VD-OPh (30 M). Cell lysates were immunoblotted for 
indicated proteins. Representative images of three independent experiments.
Control, NIK-deleted or cIAP2 overexpressing BCL-xL dependent SVEC cells (C)
were treated with ABT-737 (10M) and Q-VD-OPh (30 M, 6h) and immunostained 
for p65, minimum 300 cells were counted per condition. Quantification depicts the 
percentage nuclear p65 positive cells. Vector
CRISPR
-ctrl: n=15 individual fields, 
vector
CRISPR
-ABT-737/QVD: n=18 individual fields, NIK
CRISPR
-ctrl: n=16 individual fields, 
NIK
CRISPR
-ABT-737/QVD: n=18 individual fields, vector-ctrl: n=15 individual fields, 
vector-ABT-737/QVD: n=18 individual fields, cIAP2-ctrl: n=15 individual fields, cIAP2-
ABT-737/QVD: n=20 individual fields SEM.
Control, NIK-deleted or cIAP2 overexpressing BCL-xL dependent SVEC cells (D)
were treated with ABT-737 (10 M) and Q-VD-OPh (30 M) for 6h. Tnf expression 
was measured by qRT-PCR. Data represent the mean of triplicate samples and are 
representative of three independent experiments.
Control or cIAP2 overexpressing BCL-xL dependent SVEC cells were treated (E)
with ABT-737 (10 M) and Q-VD-OPh (30 M) as indicated and immunoblotted for 
NIK and β-Actin. Representative image of three independent experiments.
Wild-type or SMAC/OMI
-/-
 E1A/ras transformed MEFs were treated with ABT-(F)
737 (10 M) and UMI-77 (10 M) and Q-VD-OPh (30 M) for 4 h. Cell lysates were
immunoblotted for indicated proteins. Representative image of three independent 
experiments.
Wild-type or SMAC/OMI
-/-
 E1A/ras transformed MEFs were treated with ABT-(G)
737 (10 M), UMI-77 (10 M) and Q-VD-OPh (30 M)(8h) then immunostained for 
cytochrome c and p65. Cells that had undergone MOMP were scored for nuclear p65 
translocation, minimum 300 cells counted per condition. WT and SMAC/OMI
-/-
-ctrl: 
n=15 individual fields, wt and SMAC/OMI
-/-
-ABT-737/UMI-77/QVD: n=18 individual 
fields SEM.
BCL-2 dependent HeLa cells or cells transiently expressing TRAF2 together (H)
with either wild-type XIAP or XIAP BIR3 mutant (D214S E314S) were treated with 
ABT-263 (10 M) and Q-VD-OPh (30 M) for 4 h. Cell lysates were blotted for XIAP
and -Actin. Representative image of three independent experiments.
Densitometric quantification of Western blots was performed. n = 3 independent 
experiments; mean values ± S.E.M.. *p<0.05, **p<0.01, ***P<0.001; Tukey-
corrected two way ANOVA (C, G, H). Statistical source data can be found in 
Supplementary Table 5. Unprocessed original scans of blots are shown in 
Supplementary Figure 9.
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Figure 5. Mitochondrial permeabilisation initiates an NF-B dependent pro-
inflammatory response
BCL-xL dependent SVEC cells were treated with ABT-737 (10 M) and Q-VD-(A)
OPh (30 M) for 8h. Conditioned media was analysed for cytokine detection using 
Luminex assay. Data represents the mean of duplicate samples and is representative 
of two independent experiments.
BCL-xL dependent SVEC cells stably expressing IB
SR
 or empty vector (vector) (B)
were treated with ABT-737 (10 M) and Q-VD-OPh (30 M) for 8h. Conditioned 
media was then analysed for cytokine levels using Luminex assay. Data is the mean 
of duplicate samples and is representative of two independent experiments.
BCL-xL dependent SVEC cells stably expressing IB
SR
 or empty vector (PMX) (C)
were treated with ABT-737 (10 M) and Q-VD-OPh (30 M) for 6 h and mRNA levels 
of Mcp-1, Kc, Gm-csf and Tnf were measured by qRT-PCR.
BCL-xL dependent SVEC cells stably expressing IB
SR
 or PMX empty vector (D)
(vector) with ABT-737 (10 M) and Q-VD-OPh (30 M) for 8 h and Ifn, Irf7 and
Oasl1 were measured by qRT-PCR. 
BCL-xL dependent SVEC cells deleted for STING (STING
CRISPR
) or cells (E)
expressing empty vector (vector
CRISPR
), as well as 
0
 cells were treated with ABT-737 
(10 M) and Q-VD-OPh (30 M) for 6 h, immunostained for p65 and analysed by 
confocal microscopy. Quantification includes the percentage of cells with nuclear 
p65, minimum 300 cells (left graph) and 240 cells (right graph) counted per 
condition. Vector
CRISPR
, STING
CRISPR
-ctrl and ABT-737/QVD: n=15 individual fields , 
vector
CRISPR
 and STING
CRISPR
-TNF: n=11 individual fields, untreated and EtBr-ctrl and 
ABT-737/QVD: n=22 individual fields, untreated and EtBr-TNF: n=9 individual fields 
SEM.
BCL-xL dependent SVEC cells deleted for STING (STING
CRISPR
) or expressing (F)
empty vector (vector
CRISPR
) and 
0
 SVEC were treated as indicated and cell lysates 
were immunoblotted for cIAP1, XIAP and -Actin. Representative image from three 
independent experiments.
BCL-xL dependent SVEC cells deleted for STING (STING
CRISPR
) or expressing (G)
empty vector (vector
CRISPR
) were treated with ABT-737 (10 M) and Q-VD-OPh (30 
M) for 6 h and mRNA levels of Mcp-1, Kc, Gm-csf and Tnf were measured by qRT-
PCR. For (C), (D)and (G) data represent the mean of triplicate samples and are 
representative of three independent experiments.
*p<0.05, **p<0.01, ***P<0.001; Tukey-corrected  two way ANOVA (E). Statistical 
source data can be found in Supplementary Table 5. Unprocessed original scans of 
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blots are shown in Supplementary Figure 9. .
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Figure 6. MOMP dependent NF-B activity promotes macrophage activation
Bone marrow-derived macrophages (BMDMs) were incubated overnight with (A)
conditioned media (CM) from BCL-xL dependent SVEC cells that had been treated 
with ABT-737 (10 M) – CM (APO)- or ABT-737 (10 M) and Q-VD-OPh (30 M) – CM 
(CICD)- for 8 h. Expression of indicated M1 and M2 markers was determined by qRT-
PCR.
BMDMs were treated as in (A) and stained for either M1 (CD86
+
) or M2 (B)
(CD206
+
) surface markers. n=3 independent experiments; mean values ± S.E.M.
BMDMs were incubated overnight with conditioned media (CM) from vector (C)
or APAF-1 knockdown BCL-xL dependent SVEC cells that had been treated with ABT-
737 (10 M) for 8 h. qRT-PCR was performed on BMDMs to assess M1 marker 
expression.
BMDMs were incubated overnight with conditioned media (CM) from control (D)
or BAX/BAK deleted BCL-xL dependent SVEC cells that had been treated with ABT-
737 (10 M) and Q-VD-OPh (30 M) for 8 h. qRT-PCR was performed on BMDMs to 
assess M1 marker expression.
BMDMs were incubated overnight with conditioned media (CM) from vector (E)
or IB
SR
 overexpressing BCL-xL dependent SVEC cells that had been treated with ABT-
737 (10 M) and Q-VD-OPh (30 M) for 8 h. qRT-PCR was performed on BMDMs to 
assess M1 marker expression.
BMDMs were incubated overnight with conditioned media (CM) from murine (F)
primary pancreatic tumour cells (Myc-PDAC) that had been treated for 24 h with ABT-
737 (10 M) +/- Q-VD-OPh (10 M). M1/M2 status was assessed with qRT-PCR. 
BMDMs were incubated overnight with conditioned media (CM) transferred (G)
from murine primary pancreatic tumour cells (Myc-PDAC) that have been treated for 
24 h with ABT-737 (10 M) +/- Q-VD-OPh (10 M). The activation profile was 
measured by FACS, staining for either M1 surface marker (CD86
+
) or M2 surface 
marker (CD206
+
). n=3 independent experiments; mean values ± S.E.M. For 
(A)(C)(D)(E)(F) data represent the mean of triplicate samples and are representative 
of three independent experiments.
*p<0.05, **p<0.01, ***P<0.001; Tukey-corrected  one way ANOVA (B, G). Statistical 
source data can be found in Supplementary Table 5.
Figure 7. CICD displays enhanced anti-tumorigenic effects versus apoptosis
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Control (pLKO1) or APAF-1 knockdown (APAF-1
SH
) BCL-2 dependent CT26 cells (A)
were injected subcutaneously into Balb/C mice (5x10
5
 cells/mouse). Following 
tumour formation, mice were treated with either vehicle or ABT-263 (100mg/kg) for 
2 times over a 7-day period then sacrificed one-day post-final treatment. Serum 
levels of the indicated cytokines were measured by Luminex assay. n=3 independent 
experiments; mean values ± S.E.M.
Representative immunohistochemistry images (n=3 mice) of CD3 staining (T (B)
cells), taken from control (pLKO1) or pLKO1-shAPAF-1 (APAF-1
SH
) BCL-2 dependent 
CT26 cell tumour sections, following vehicle or ABT-263 (100mg/kg) treatment, 2 
times in a week. Scale bar represents 100M.
Control (pLKO1) or pLKO1-shAPAF-1 (APAF-1
SH
) BCL-2 dependent CT26 cells (C)
were injected subcutaneously into Balb/C mice. Following tumour formation, mice 
were treated with vehicle or ABT-263 for 2 times in a 7-day period and sacrificed one 
day post-final treatment. T cell tumour infiltration was measured by flow-cytometry 
(CD3
+
DAPI
-
 cells). Vector-vehicle and ABT-263, APAF-1
SH
-vehicle: n=9 mice, APAF-1
SH
-
ABT-263: n=8 mice  SD.
BCL-2 dependent CT26 cells (wt vs APAF-1
SH
) were injected into mice and (D)
treated with either vehicle or ABT-263 (100mg/kg) 2 times/week for a total of two 
weeks. Tumour growth was determined every 2 days by measuring the tumour 
volume (mm
3
). WT-vehicle, APAF-1
SH
-vehicle and ABT-263: n= 10 mice, wt-ABT-263: 
n=9 mice SEM from one experiment, repeated independently. Arrows indicate 
time of treatment.
Individual mouse tumour growth from (D) is shown. Post-treatment, each (E)
individual tumour was normalized (%) to the initial volume (mm
3
) obtained the first 
day of treatment (100% normalized tumour volume). Arrows indicate time of 
treatment. 
*p<0.05, **p<0.01, ***P<0.001; Tukey-corrected  two way ANOVA (C, D). 
26
Figure 8. CICD anti-tumourigenic effects requires NF-B and intact immunity
Vector or APAF-1
SH
BCL-2 dependent CT26 cells were injected into Balb/C (A)
mice. Tumour bearing mice were treated with vehicle or ABT-263 (4 times over 2 
weeks). Mice were sacrificed at day 13 post-treatment and split into responder (R) 
and non-responder (NR) groups. Total macrophage tumour infiltration (F4/80
+
) and 
M1-like macrophage activation status (NOS2
+
, CD86
+
 and MHC-II
+
) was measured by 
flow cytometry. 
Samples generated in 8A were analysed for tumour-infiltrating activated CD4
+
(B)
T cells (IFNγ
+
). 
Samples generated in 8A were analysed for tumour-infiltrating activated CD8
+
(C)
T cells (IFNγ
+
). For A-C The number of live infiltrated immune cells were measured by 
FACS and subsequently normalized to total live tumour cells and tumour weight. 
Data represents the mean  SD of tumours; n=6-9 mice per group (individual n 
number per sub-group is provided in the figure).
BCL-2 dependent APAF-1
SH
CT26 cells were injected into NSG mice. Tumour (D)
bearing mice were treated with vehicle or ABT-263. Data represents the mean SD 
of tumour volume (mm
3
). Arrows indicate treatment points; n=10 mice per group.
BCL-2 dependent APAF-1
SH
CT26 cells were injected into Balb/C mice. Tumour (E)
bearing mice were pre-treated with isotype control or anti-Thy.1. One day later mice 
were treated with vehicle or ABT-263 (black arrows indicate treatment points) 
together with isotype control or anti-Thy.1 (red arrows indicate treatment points). 
Tumour growth was monitored every other day. APAF-1
SH
 + Isotype ctrl + ABT-263: 
n=10 mice, APAF-1
SH
 + anti-Thy.1 + ABT-263: n=9 mice SEM.
BCL-2 dependent APAF-1
SH
CT26 cells and expressing vector or NEMO shRNA (F)
were injected into mice. Tumour bearing mice were treated with vehicle or ABT-263. 
Individual mouse tumour growth is shown. Post-treatment, each tumour was 
normalized (%) to the initial tumour volume (each set at 100%). Arrows indicate time 
of treatment and asterisks tumours that grew over 500% of the initial volume. APAF-
1
SH
-vector + vehicle: n=9 mice, APAF-1
SH
-vector + ABT-263: n=10 mice, APAF-1
SH
-
NEMO
SH 
+ vehicle: n=8 mice, APAF-1
SH
-NEMO
SH 
+ ABT-263: n=8 mice.
In silico analysis of clinical data from renal cell carcinoma patients using the (G)
TCPA database. 
*p<0.05, **p<0.01, ***P<0.001; Dunn’s-corrected Kruskal-Wallis (A, B, C), Tukey-
corrected  two way ANOVA (E), Spearman’s rank test (correlation), Cox and Log-Rank 
test (Kaplan Meier curves) (G).
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1Methods
Cell lines, plasmids and reagents
SVEC, MEF, HeLa and primary Myc-PDAC cells were cultured in DMEM high 
glucose medium, CT26 cells were cultured in RPMI high glucose medium. Culture 
media were supplemented with 10% FCS, 2 mM glutamine, 1 mM sodium pyruvate, 
50μM β-mercaptoethanol, penicillin (10000 units/mL) and streptomycin (10000 
units/mL). Reagents (Supplemental Table 1) used were as follows: ABT-737, Q-VD-
OPh, ABT-263 - APEX Bio, UMI-77 - Selleckchem, MG132 - Calbiochem, necrostatin-1 - 
Sigma, Enbrel - Pfizer, murine and human TNF - Peprotech, murine-CSF - Miltenyi 
Biotec -MACS, PMA - Sigma, Ionomycin-Santa Cruz, Brefeldin A – eBioscience, LEAF™ 
Purified anti-mouse IFN-β Antibody, LEAF™ Purified Armenian Hamster IgG Isotype 
control Antibody - Biolegend, collagenase - Sigma, SMAC-mimetic (SM-83) has been 
previously described 
37
. Using pTIZ-cIAP2 and pBabe-puro-IB
SR
 as template, cIAP2 
and IB
SR
 were cloned into PMX using PCR/restriction digest based cloning. For 
lentiviral transduction the following plasmids were used pLKO-puro, pLKO-RIPK3
SH
(mouse SH-RNA, TRCN0000022535), pLKO1-blasti (mouse non-target control), pLKO1-
blasti-APAF-1
SH
 (mouse SH-RNA, TRCN00000012278), pLKO-blasti-RIPK3
SH
 (mouse SH-
RNA, TRCN00000022538), pLKO1-puro (non-target control), pLKO1-puro-APAF-1
SH
(mouse SH-RNA, TRCN00000012278), pLKO1-blasti-NEMO
SH
 (mouse SH-RNA, 
TRCN0000088811) (Supplemental Table 2). The puromycin cassette in the pLKO1 
vector was substituted with blasticidin cassette using PCR/restriction digest based 
cloning. For CRISPR/Cas9 based genome editing the following sequences were cloned 
into LentiCRISPRv1-puro (Addgene, 49535, 
38
) targeting mouse Caspase-9: 
CTTCACGCGCGACATGATCG, mouse NIK: TCGCTGGCCAGCGATCGCTC, or 
LentiCRISPRv2-puro (Addgene, 52961,
39
), targeting mouse BAX: 
CAACTTCAACTGGGGCCGCG, mouse BAK: GCGCTACGACACAGAGTTCC, mouse STING: 
AGCGGTGACCTCTGGGCCGT, mouse IKKβ: TCACACATACCCCGTGACGG, mouse 
NEMO: TGGCCTTGTCCAACCAGCGG, mouse p65: ATCGAACAGCCGAAGCAACG, mouse 
p100/p52: AAGACAGCGGGTTCCGTGCG, mouse RelB: AGCGGCCCTCGCACTCGTAG, 
pRRL M1 Scramble CRISPR-Cas9-T2A-puro, pRRL M1 Scramble CRISPR-Cas9-T2A-puro- 
oligo sequence targeting mouse MLKL: GCACACGGTTTCCTAGACGC (Supplemental 
2Table 3). PEF-human XIAP wt-FLAG (C-ter) or PEF-human XIAP_D214S_E314S (BIR3 
mutant)-FLAG (C-ter) provided by Dr. John Silke
20
. General reagents, siRNA/shRNA
reagents, CRISPR targeting sequences and neutralising antibodies are also described 
in Supplemental Tables 1,2, 3 and 6 respectively. No cell lines were authenticated. 
Cell lines were tested multiple times over the study for mycoplasma contamination. 
No cell lines used in this study were found in the database of commonly misidentified 
cell lines that is maintained by ICLAC.
Retroviral and lentiviral transduction
Phoenix Eco (for retroviral transduction of mouse cell lines) and Phoenix 
Ampho (for human cells) were transfected with 5 μg of selected plasmids, using 
Lipofectamine 2000 (Invitrogen). After two days, the viral supernatant was filtered 
and used to infect cells, in the presence of 1 μg/mL polybrene. After two rounds of 
infection antibiotic treatment was applied as follows: 200 ug/mL Zeocin  (Invitrogen) 
for LZRS vectors and 8 ug/mL of blasticidin for PMX vectors.  For CT26 cell 
transductions, 293T cells were used for virus production: the indicated plasmids were 
co-transfected and the packaging plasmids pVSVG (Addgene 12260) and HIV (gag-
pol). For lentiviral transduction, 293T cells were co-transfected with selected 
plasmids and 2 μg of pVSVG (Addgene 12260) and 3.72 μg of psPAX2 (Addgene 8454) 
using Lipofectamine 2000 (Invitrogen). Viral infection and subsequent selection was 
performed as above. For positive clone selection blasticidin (8 μg/mL) or puromycin 
(10μg/mL) was used. CRISPR/Cas9 KO cells were generated by lentiviral transduction 
as described above and positive clones were selected with puromycin (1μg/mL).
 Generation of ρ
0
 cells
SVEC cells were cultured in the presence of ethidium bromide (EtBr, 500 ng / 
mL) for a week to generate mitochondrial DNA (mtDNA) depleted cells (ρ
0
 cells). 
Total DNA was extracted and qPCR was performed. The mitochondrial content was 
measured by the ratio of mtDNA (Dloop) vs genomic DNA (Tert) as measured by 
3qPCR. Primers: Dloop_FW: AATCTACCATCCTCCGTGAAACC, Dloop_REV: 
TCAGTTTAGCTACCCCCAAGTTTAA, Tert_FW: CTAGCTCATGTGTCAAGACCCTCTT, 
Tert_REV: GCCAGCACGTTTCTCTCGTT.
Bone marrow-derived macrophage (BMDM) isolation 
Macrophages were generated from bone marrow precursors as described 
previously 
40
. Briefly, bone marrow stem cells were isolated from mice by flushing the 
bone marrow with PBS. Bone marrow stem cells were differentiated into 
macrophages by culturing them for 6 days in RPMI medium containing M-CSF (10 
ng/mL). Media (containing M-CSF) was replaced after 3 days. Where indicated, 
BMDM’s were isolated from wild-type and Tnfr1
−/−
 mice as previously described 
41
.
qRT-PCR
RNA was isolated from cells using QIAGEN RNeasy Mini Kit (Qiagen) and used 
for cDNA synthesis and PCR with DyNAmo SYBR Green 2-step qRT-PCR kit (Thermo 
Fisher Scientific). PCR was performed on a C1000Tm Thermal Cycler (CFX96 Tm-Real 
time system, BioRad) as following: 3 min at 95 
o
C, followed by 40 cycles of 20 sec at 
95
 o
C, 30 sec at 57
 o
C, 30 sec at 72
 o
C and final 5 min at 72
 o
C. Relative mRNA 
quantification was performed by using the 2^-ddCT method for multiple genes.
Primer sequences are provided in the supplemental experimental procedures
(Supplemental Table 4). 
Microscopy
Cells were fixed in 4% PFA/PBS for 10 minutes and then permeabilised with 
0.2% Triton/PBS for 10 minutes followed by 1 hour incubation at room temperature 
with blocking buffer (2% BSA/PBS). Cells were incubated overnight at 4
o
C with the 
following antibodies: NFκB-p65 (sc-372, Santa Cruz, 1/300 dilution in blocking buffer), 
4NFκB-p65 (8242P, Cell Signalling, 1/400 dilution in blocking buffer) and cytochrome c
(556432, BD Biosciences, 1/300 dilution in blocking buffer). The secondary antibodies 
used for detection were Alexa Fluor 594 goat anti-rabbit (A11037, Invitrogen, 1/300 
dilution), Alexa Fluor 594 goat anti-mouse (A11032, Invitrogen, 1/300 dilution), Alexa 
Fluor 647 goat anti-mouse (A21236, Invitrogen, 1/300 dilution). DAPI (Vector 
Lavoratories, H-1200) was used for nuclear staining. Cells undergoing MOMP were 
scored by the diffusion or loss of cytochrome c staining. Cells undergo MOMP were 
scored as positive with nuclear p65 translocation by co-staining with DAPI. As a 
positive control of p65 nuclear translocation TNF treatment was used. Data 
represents the mean of the total number of fields obtained from three independent 
experiments. Images were taken using a Nikon A1R confocal microscope and 
analyzed with Image J 1.47i. List of antibodies used is also provided in Supplemental 
Table 6.
Western blotting
Cells were lysed in NP-40 lysis buffer (1% NP-40, 1mM EDTA, 150mM NaCl, 
50mM Tris pH7.4, 1mM PMSF and complete protease inhibitors (Roche)). Protein 
concentration was determined using the Bradford (BioRad) assay. Proteins were 
separated by SDS-PAGE and transferred onto nitrocellulose membrane. The 
membranes were blocked and incubated with one of the following primary 
antibodies overnight in 4
o
C: anti-PARP (9532, Cell Signalling, 1/1000), anti-β-Actin 
(8691001, MP Biomedicals, 1/10000 dilution), anti-α-Tubulin (T5168, Sigma, 1/10000 
dilution), anti-Mcl-1 (sc-819, Santa Cruz, 1/1000 dilution), anti-RIPK3 (ADI-905-242-
100, Enzo life sciences, 1/1000 dilution), anti-MLKL (ab172868, Abcam, 1/500 
dilution), anti-BAK (12105, Cell Signalling, 1/1000 dilution), anti-BAX (Santa Cruz, sc-
493, 1/1000 dilution), anti-Caspase-9 (9504P, Cell Signalling, 1/1000 dilution), anti-p-I
κBα (2859, Cell Signaling, 1/1000), anti-IκBα (9242, Cell Signaling, 1/1000), anti-NIK 
(4994P, Cell Signalling, 1/500 dilution), anti-cIAP1 (ALX-803-335-C100, ENZO, 1/1000
dilution), anti-Omi (2176, Cell Signalling, 1/1000 dilution), anti-SMAC (32023, Abcam, 
1/1000 dilution), anti-STING (13467S, Cell Signalling, 1/1000 dilution), anti-APAF-1 
5(8723, Cell Signalling, 1/500 dilution), anti-NFκB-p65 (8242P, Cell Signalling, 1/1000 
dilution), anti-p100/p52 (4882, Cell Signalling, 1/500 dilution), anti-NEMO (2685, New 
England Biolabs, 1/1000), anti-IKKβ (MAB7155, R&D systems, 1/1000), anti-RelB 
(4954, Cell Signalling, 1/500 dilution), anti-BID (raised against a GST fusion protein of 
full-length human BID
42
), anti-cleaved caspase-3 (9661, Cell Signaling, 1/1000 
dilution), anti-cleaved caspase-7 (9491, Cell Signaling, 1/1000 dilution). Protein 
detection was achieved with chemoluminescence by the use of HRP-linked secondary 
antibodies and ECL. Where indicated Image J 1.47i was used for densitometry 
analysis. List of antibodies used is also provided in Supplemental Table 6.
Cell viability assays
Cell viability was determined either by flow cytometry  (FACSCalibur, BD 
Biosciences, San Jose, CA) or IncuCyte FLR imaging system (Essen Bioscience, Ann 
Arbor, MI), using the non-cell-permeable nuclear staining procedures: 10 μg/mL
Propidium Iodide (PI, P3566, Invitrogen - flow-cytometry) or 30nM SYTOX Green (SG, 
S7020, Invitrogen - Incucyte), respectively, according to the manufacturer’s 
protocols. The number of SYTOX Green positive cells was normalized to the 
confluency factor and the percentage of SYTOX Green-positive cells was calculated 
against a control that achieved 100% cell death. FACS Gating strategy for PI staining 
is outlined in Supplemental Figure 8.
Flow cytometry
Flow cytometry was used to characterize the profile of immune cells including 
macrophages, NK and T cells. BMDMs M1/M2 activation status was analysed using 
FACSCalibur (BD Biosciences, San Jose, CA) with the following antibodies:  APC-CD86-
clone: GL1 (B185438, Biolegend, 1/200 dilution), and FITC-CD206 (MMR)-clone: 
C068C2 (141703, Biolegend, 1/200 dilution). Subcutaneous CT26 tumours were 
isolated from Balb/C mice, homogenised and analyzed for immune cell infiltration 
6(M1/M2 macrophages, T cells) by BD FACSVerse (BD Biosciences, USA) using the 
following antibodies: purified anti-mouse CD16/32 / Fc-Block (101302, Biolegend, 
1/200 dilution), PerCP/Cy5.5-F4/80- clone BM8 (123128, BD Biosciences, 1/200 
dilution), APC-MHC-II/ I-A, I-E, clone: M5/114.15.2 (107614, BD Biosciences, 1/200 
dilution), and FITC-CD2O6 (MMR)-clone: C068C2 (141703, Biolegend, 1/200 dilution), 
Biotin-Hamster CD3e-clone:145-2C11,
(553060, BD-Pharmigen, 1/200 dilution), PE-Streptavidin (405203, Biolegend, 1/2000 
dilution). Tumour infiltrated macrophages were further analysed for M1/M2 
activation status using the Attune NxT (Thermo Fischer Scientific) flow cytometer 
with the following antibodies: PerCP/Cy5.5-F4/80-clone:BM8 (123128, BD 
Biosciences, 1/200 dilution) PECy5-MHC-II/ I-A, I-E- clone: M5/114.15.2
(107612, Biolegend, 1/200 dilution), APCCy7-CD86-clone: GL-1 (105030, Biolegend, 
1/200 dilution), APC-NOS2-clone: CXNFT (17-5920-82, eBioscience, 1/200 dilution), 
Polyclonal Sheep IgG-PE-Arg1 (IC5868P, R&D Systems, 1/200 dilution) and FITC-
CD2O6)-clone: C068C2 (MMR) (141703, Biolegend, 1/200 dilution), DAPI (0.5 µg/ml) 
or Zombie Yellow (423104,Biolegend, 1/500 dilution) were used as cell death dyes to 
discriminate live/dead cell populations. FACS Gating strategy is outlined in
Supplemental Figure 8. List of antibodies used is provided in Supplemental Table 6.
T-cell activation
Freshly isolated tumours were digested with collagenase (1.5 mg/ml) for 30 minutes 
in 37
o
C and subsequently homogenised. 2 x 10
6
 isolated cells were treated with 50 
ng/ml PMA, 1 µg/ml ionomycin and 1X Brefeldin A in complete RPMI medium and 
incubated for 6 hours in corning 96-well plate. Cells were collected, stained with 
Zombie Yellow cell death dye (1/500 dilution) and analysed by flow cytometry 
(Attune NxT, Thermo Fischer Scientific) with the following antibodies: APC-CD3-clone: 
17A2 (100235, Biolegend, 1/200 dilution), PE-CD4, clone: RM4-4 (116006, Biolegend, 
1/200 dilution), PECy7-CD8- clone: 53-6.7 (100721, Biolegend, 1/200 dilution), 
Brilliant Violet 421-IFNγ- clone: XMG1.2 (505829, Biolegend, 1/200 dilution), FITC-
7Granzyme B- clone; GB11 (515403, Biolegend, 1/200). FACS Gating strategy is 
outlined in Supplemental Figure 8. List of antibodies used is also provided in 
Supplemental Table 6.
ELISA and Luminex assay
Conditioned media was concentrated using the Amicon Ultra-4 Centrifugal 
Filter Unit with Ultracel-3 membrane (UFC800324, 3 kDa cut-off, Milipore), according 
to the manufacturer’s protocol. TNF protein concentration was measured using the 
Murine TNF Mini ELISA Development Kit (900-M54, Peprotech), according to the 
manufacturer's protocol. For the Luminex assay a mouse Cytokine Magnetic 20-Plex 
Panel (LMC0006M, Invitrogen) was used to measure cytokine levels in mouse serum, 
and tissue culture supernatant (condensed with the Amicon Ultra-4 Centrifugal Filter 
Unit), according to the provided protocol.
Luciferase assay
SVEC cells (2 x 10
6
 cells in 10cm plate) were transfected with 2 μg of empty 
vector (PGL3) or NF-B reporters (reporter 1: PGL3-TNF - TNF promoter binding sites, 
reporter 2: PGL3-NP3 - NF-B binding sites). Luciferase activity was measured by 
Glomax / Veritas Microplate Luminometer, according to the manufacturer’s protocol 
(luciferase assay kit E1500, Promega). Each obtained value was normalized to μg of 
protein of each individual sample and empty vector. 
Immunohistochemistry (IHC)
IHC was performed on 10% buffer-formalin fixed, paraffin-embedded sections 
(4 μm thick). Staining was performed using a Dako autostainer. Anti-caspase-3, ASP-
8175 (9661, Cell Signalling) was used at 1/50 dilution after antigen retrieval with PT 
buffer (pH 6.0). Anti-CD3 (VP-RM01, Vector Labs) was used at 1/60 dilution after 
antigen retrieval with PT buffer (pH 6.0). Anti-F4/80  (ab6640, AbCam) was used at 
1/400 dilution after antigen retrieval with Proteinase K for 10 minutes. 
In silico analysis
Protein correlation analysis as well as survival curves of clinical samples 
(Kidney renal cell carcinoma), have been generated by using the TCPA (The Cancer 
Proteome Atlas) bioinformatic-platform provided by MD Anderson Cancer Centre 
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.
In vivo experiments
Experiments with Balb/C mice were done in accordance with UK regulations 
under project license PPL 70/8645, ethical review (University of Glasgow) and the EU 
Directive 2010. To observe the effect of Apaf1 on tumour growth in vivo, 0.5 ×
 10
6
CT26 GFP tBID 2A BCL-2 (proficient) and CT26 GFP tBID 2 BCL-2 APAF-1
SH
(deficient) cells were suspended in 200 µl PBS and were subcutaneously implanted 
into the flank of 6 week old Balb/C female mice (Charles River, UK). Once tumour 
volumes reached approximate 100 mm
3
(length × width
2
/2), mice were ranked and 
randomly divided into four groups. Mice were orally dosed four times over a two-
week period with 100 µl Vehicle (10% ethanol, 30% PEG glycol 400, and 60% Phosal 
50 PG) or ABT-263 (100mg/kg, diluted in vehicle). Tumours were measured by caliper 
thrice weekly and mice were killed humanely when tumours reached clinical 
endpoint of predetermined size or ulceration. Furthermore, mice that were orally 
dosed two times over a one-week period of time were humanely killed and tumours 
were assessed for immune cell infiltration either by FACS or by IHC. 
For NOD scid gamma c
-/-
(NSG) experiments, 6 week old NSG mice were 
9subcutaneously injected with 0.5 × 10
6
 APAF1 KD CT26 cells expressing GFP-tBID 2A 
Bcl2 cells resuspended in 200 μl of PBS. Once tumor volume reached approximately 
100 mm
3
 (length x width
2
/2), mice were given 100 μl of Vehicle (10% Ethanol, 30% 
PEG glicol 400, and 60% Phosal 50 PG) or ABT-263 (diluted in vehicle) orally four times 
over a one week period. The animals were then inspected three times a week for 
tumor development. Once tumors started to develop they were measured every day 
using a caliper. Mice were humanely killed when tumors reached a predetermined 
size. 
In vivo T-cell depletion
As described previously, CT26 cells expressing eGFP-tBID 2A BCL-2 together with 
pLKO1-shAPAF-1 (APAF-1
SH
) were injected subcutaneously into 6 weeks old Balb/C 
mice (5x10
5
 cells/mouse). Once tumor volume reached approximately 100 mm
3
Following tumour formation, mice were initially treated with 400 g of isotype 
control or anti-Thy.1 (I.P injection) and then were continued to be treated with 200 
g twice per week. Efficiency of T cell depletion was checked by flow cytometric 
analysis of spleen samples. FACS Gating strategy is outlined in Supplemental Figure 8.
List of antibodies used is provided in Supplemental Table 6.
Statistics and Reproducibility
For the in vitro experiments, normal distribution was assumed, whereas for 
the in vivo experiments normal distribution has been tested prior the use of the 
appropriate statistical test. Two-tailed unpaired t-test was used for comparison of 
two groups, whereas the one-, two-way Analysis of Variance (ANOVA) and non-
parametric one-way ANOVA (Kruskal-Wallis) was used for comparison of multiple 
groups. Spearman’s rank test was used for correlation analysis. Cox and Log-Rank p-
value were used for survival curve (Kaplan Meier) analyses. Finally, two-tailed Chi-
Square was used to determine any significant differences in frequencies of complete 
tumour regression between two groups. Analyses were performed using Prism 6.0 
software (GraphPad). 
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Data availability
Source data for Figures 2d-e, 2g-i, 3f, 3h, 4d, 5a-d, 5g, 6a, 6c-f and 
Supplemental Figures S1K, S4a-d, S4g-h, S4j-l, and S5d-l has been provided as 
Supplemental Table 5. All other data supporting the findings are available from the 
corresponding author upon reasonable request.
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Figure 7 
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Figure 8 
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